292 related articles for article (PubMed ID: 36302155)
1. A bench to bedside perspective on anthracycline chemotherapy-mediated cardiovascular dysfunction: challenges and opportunities. A symposium review.
Clayton ZS; Ade CJ; Dieli-Conwright CM; Mathelier HM
J Appl Physiol (1985); 2022 Dec; 133(6):1415-1429. PubMed ID: 36302155
[TBL] [Abstract][Full Text] [Related]
2. Anthracycline chemotherapy-mediated vascular dysfunction as a model of accelerated vascular aging.
Clayton ZS; Hutton DA; Mahoney SA; Seals DR
Aging Cancer; 2021 Jun; 2(1-2):45-69. PubMed ID: 34212156
[TBL] [Abstract][Full Text] [Related]
3. Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy.
Koelwyn GJ; Lewis NC; Ellard SL; Jones LW; Gelinas JC; Rolf JD; Melzer B; Thomas SM; Douglas PS; Khouri MG; Eves ND
Oncologist; 2016 Feb; 21(2):141-9. PubMed ID: 26764251
[TBL] [Abstract][Full Text] [Related]
4. Anthracycline chemotherapy, vascular dysfunction and cognitive impairment: burgeoning topics and future directions.
Maurer GS; Clayton ZS
Future Cardiol; 2023 Sep; 19(11):547-566. PubMed ID: 36354315
[TBL] [Abstract][Full Text] [Related]
5. Effects of high-intensity interval training on vascular function in breast cancer survivors undergoing anthracycline chemotherapy: design of a pilot study.
Lee K; Kang I; Mortimer JE; Sattler F; Mack WJ; Fitzsimons LA; Salem G; Dieli-Conwright CM
BMJ Open; 2018 Jun; 8(6):e022622. PubMed ID: 29961039
[TBL] [Abstract][Full Text] [Related]
6. Anthracycline causes impaired vascular endothelial function and aortic stiffness in long term survivors of childhood cancer.
Jenei Z; Bárdi E; Magyar MT; Horváth A; Paragh G; Kiss C
Pathol Oncol Res; 2013 Jul; 19(3):375-83. PubMed ID: 23242567
[TBL] [Abstract][Full Text] [Related]
7. Increased arterial stiffness in children treated with anthracyclines for malignant disease.
Herceg-Cavrak V; Ahel V; Batinica M; Matec L; Kardos D
Coll Antropol; 2011 Jun; 35(2):389-95. PubMed ID: 21755708
[TBL] [Abstract][Full Text] [Related]
8. Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.
Upshaw JN
Curr Oncol Rep; 2020 Jun; 22(7):72. PubMed ID: 32564220
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-induced cardiotoxicity in children.
Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
[TBL] [Abstract][Full Text] [Related]
10. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-related cardiotoxicity: are Australian practitioners missing the point?
Conyers R; Costello B; La Gerche A; Tripaydonis A; Burns C; Ludlow L; Lange P; Ekert P; Mechinaud F; Cheung M; Martin M; Elliot D
Intern Med J; 2017 Oct; 47(10):1166-1172. PubMed ID: 28485067
[TBL] [Abstract][Full Text] [Related]
12. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
Drafts BC; Twomley KM; D'Agostino R; Lawrence J; Avis N; Ellis LR; Thohan V; Jordan J; Melin SA; Torti FM; Little WC; Hamilton CA; Hundley WG
JACC Cardiovasc Imaging; 2013 Aug; 6(8):877-85. PubMed ID: 23643285
[TBL] [Abstract][Full Text] [Related]
13. Cardioprotection in cancer therapy: novel insights with anthracyclines.
Raber I; Asnani A
Cardiovasc Res; 2019 Apr; 115(5):915-921. PubMed ID: 30726931
[TBL] [Abstract][Full Text] [Related]
14. Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?
Basar EZ; Corapcioglu F; Babaoglu K; Anik Y; Gorur Daglioz G; Dedeoglu R
Pediatr Hematol Oncol; 2014 Apr; 31(3):237-52. PubMed ID: 24499452
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline-related cardiotoxicity in childhood cancer survivors.
Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
[TBL] [Abstract][Full Text] [Related]
16. Critical Illness and Cardiac Dysfunction in Anthracycline-Exposed Pediatric Oncology Patients.
Wolfe KK; Reichek J; Marsillio LE
Pediatr Crit Care Med; 2019 Jul; 20(7):595-602. PubMed ID: 30925571
[TBL] [Abstract][Full Text] [Related]
17. Anthracycline chemotherapy impairs the structure and diastolic function of the left ventricle and induces negative arterial remodelling.
Mizia-Stec K; Gościńska A; Mizia M; Haberka M; Chmiel A; Poborski W; Gąsior Z
Kardiol Pol; 2013; 71(7):681-90. PubMed ID: 23907900
[TBL] [Abstract][Full Text] [Related]
18. Age-Related Considerations in Cardio-Oncology.
Screever EM; Meijers WC; Moslehi JJ
J Cardiovasc Pharmacol Ther; 2021 Mar; 26(2):103-113. PubMed ID: 33124480
[TBL] [Abstract][Full Text] [Related]
19. Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patients.
Kang M; Kim KI; Song YC; Shin WG; Oh JM
J Chemother; 2012 Oct; 24(5):292-6. PubMed ID: 23182049
[TBL] [Abstract][Full Text] [Related]
20. Anticancer Therapy-Related Increases in Arterial Stiffness: A Systematic Review and Meta-Analysis.
Parr SK; Liang J; Schadler KL; Gilchrist SC; Steele CC; Ade CJ
J Am Heart Assoc; 2020 Jul; 9(14):e015598. PubMed ID: 32648507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
